Business
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT. A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the co
About this update from Kailera Therapeutics, Inc.
[{"type":"image","alt":"Kailera Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kailera Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/e0d3565801d0638c4e04d01b2e1d4aa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5O.ZTO.tHE889btlPM9sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/e0d3565801d0638c4e04d01b2e1d4aa0","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5O.ZTO.tHE889btlPM9sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/e0d3565801d0638c4e04d01b2e1d4aa0","width":300,"height":169}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.","length":355,"tagName":"p"},{"type":"text","content":"A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.","length":176,"tagName":"p"},{"type":"text","content":"About Kailera Therapeutics","length":26,"tagName":"p"},{"type":"text","content":"Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral...